- Diana Brainard, M.D., brings extensive expertise in immunology, virology, and infectious disease
- Jeffrey Bornstein adds broad global financial, strategic, and operational experience
Cambridge, Mass., July 14, 2020 - AlloVir, a late clinical-stage cell therapy company, announced the addition of Diana M. Brainard, M.D., and Jeffrey Bornstein to its Board of Directors. Dr. Brainard brings more than 15 years of experience in virology, immunology, infectious disease, and global drug development while Mr. Bornstein provides extensive global operational and financial expertise across a broad range of leading businesses.
“We’re thrilled to welcome Diana and Jeff to our Board of Directors as we prepare to enter multiple late-stage clinical trials across our portfolio of highly innovative allogeneic cell therapies with an ambition to build a global commercial footprint,” said David Hallal, Chairman and Chief Executive Officer of AlloVir. “These two seasoned executives bring extensive expertise and unique perspectives from leading global businesses that will be invaluable during this next phase of our accelerated growth.”
Dr. Brainard is Senior Vice President and Head of the Virology Therapeutic Area at Gilead Sciences, Inc., where she oversees the clinical development of novel therapeutic, preventative, and curative approaches for HIV, hepatitis B and C, and emerging and respiratory viruses. Most recently, Dr. Brainard has been leading the global clinical development for remdesivir for COVID-19, which resulted in the first regulatory approval and commercial launch for a therapy for patients infected with SARS-CoV-2. Dr. Brainard joined Gilead in 2010 in the Liver Diseases therapeutic area, where she led the clinical development of the direct acting antiviral therapies for chronic hepatitis C infection. Prior to Gilead, she worked for Merck in early drug development both in clinical pharmacology and as the Infectious Diseases lead in translational medicine. She is the author of more than 200 scientific publications and has a passion for advancing therapies for life-threatening diseases. Dr. Brainard received Board Certification in Internal Medicine and Infectious Diseases. Following completion of her medical training, she was on faculty at Harvard Medical School, where she conducted NIH-funded research on HIV immunology and T cell trafficking. Dr. Brainard received a B.A. in comparative literature from Brown University and an M.D. from Tulane University School of Medicine.
“AlloVir has built a highly innovative technology platform with the potential to quickly assess and respond to existing and emerging viral diseases and a promising pipeline of cell therapy clinical candidates,” said Dr. Brainard. “I look forward to working with the company as it advances its clinical development on behalf of patients suffering from devastating viral diseases.”
Mr. Bornstein currently serves as Managing Partner at Generation Capital Partners and Founder and Principal of Whipstick Ventures LLC. Mr. Bornstein had an accomplished career with General Electric (GE), first joining the organization in 1989, rising from analyst to Vice Chairman and Chief Financial Officer of one of the world’s largest and most complex organizations. During his tenure at GE, Mr. Bornstein worked towards reimagining and rebuilding the company into a sustainable industrial technology business. After over thirty years in the industry, Bornstein has diverse leadership experiences including building growth businesses, mergers and acquisitions, restructuring, capital markets, and change leadership. Mr. Bornstein is well known for inspiring and attracting talented and committed teams with a legacy of developing successful leaders both internally and externally and a unique ability to connect, lead and engage all levels of the organization. He is a trustee of Northeastern University, and a member of the Board of Directors of buildOn, Inc. Mr. Bornstein received a B.S. in Business Administration from Northeastern University.
“AlloVir has already begun to set up a nimble and efficient organization to support global development and, if approved, commercialization for their highly innovative allogeneic, off-the-shelf virus-specific T cell therapy candidates,” said Mr. Bornstein. “This is an exciting time to join the Board as we work to build a truly global company with an aim to partner with physicians, hospitals, and government payers to serve patients around the world.”
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com.